. | . | ACR at EOT . | |||||
---|---|---|---|---|---|---|---|
. | . | Saxagliptin . | Placebo . | ||||
ACR at baseline (mg/g) . | P value . | <30 . | 30–300 . | >300 . | <30 . | 30–300 . | >300 . |
<30 | 0.021* | 3,152 (84.2)a | 555 (14.8)d | 36 (1.0)e | 2,993 (82.2)a | 617 (16.9)d | 31 (0.8)e |
30–300 | <0.001** | 451 (28.9)b | 929 (59.5)a | 181 (11.6)d | 352 (23.4)b | 904 (60.1)a | 249 (16.5)d |
>300 | 0.049*** | 23 (4.3)c | 148 (27.7)b | 363 (68.0)a | 15 (3.0)c | 115 (23.4)b | 362 (73.6)a |
. | . | ACR at EOT . | |||||
---|---|---|---|---|---|---|---|
. | . | Saxagliptin . | Placebo . | ||||
ACR at baseline (mg/g) . | P value . | <30 . | 30–300 . | >300 . | <30 . | 30–300 . | >300 . |
<30 | 0.021* | 3,152 (84.2)a | 555 (14.8)d | 36 (1.0)e | 2,993 (82.2)a | 617 (16.9)d | 31 (0.8)e |
30–300 | <0.001** | 451 (28.9)b | 929 (59.5)a | 181 (11.6)d | 352 (23.4)b | 904 (60.1)a | 249 (16.5)d |
>300 | 0.049*** | 23 (4.3)c | 148 (27.7)b | 363 (68.0)a | 15 (3.0)c | 115 (23.4)b | 362 (73.6)a |
*P value is based on a two-tailed normal distribution approximation test for the proportion of patients who worsened;
**P value is based on a χ2 test for independence;
***P value is based on a two-tailed normal distribution approximation test for the proportion of patients who improved.
P values were calculated for each level of ACR at baseline separately.
aThe number of patients (%) at each ACR category at baseline, with no change in ACR category to EOT.
bThe number of patients (%) at each ACR category at baseline, with improvement in one ACR category to EOT.
cThe number of patients (%) at each ACR category at baseline, with improvement in two ACR categories to EOT.
dThe number of patients (%) at each ACR category at baseline, with worsening in one ACR category to EOT.
eThe number of patients (%) at each ACR category at baseline, with worsening in two ACR categories to EOT.